Greenwood Genetic Center

Greenville, South Carolina 29605

0 studies enrolling now · 9 studies all time

What they study most

22Q11.2 Deletion Syndrome, Fabry Disease, Fragile X Syndrome, MPS IVA, MPS VI, Maroteaux Lamy Syndrome, Morquio Syndrome A

Studies at this site

• A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome — Completed
• Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS — Running, not enrolling
• Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) — Completed
• A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome — Completed
• Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome — Completed
• An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome — Running, not enrolling
• Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease — Completed
• Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) — Completed
• Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome — Completed